fasudil has been researched along with Hibernation, Myocardial in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shibata, I | 1 |
| Yoshitomi, O | 1 |
| Use, T | 1 |
| Ureshino, H | 1 |
| Cho, S | 1 |
| Maekawa, T | 1 |
| Hara, T | 1 |
| Sumikawa, K | 1 |
1 other study available for fasudil and Hibernation, Myocardial
| Article | Year |
|---|---|
Administration of the Rho-kinase inhibitor fasudil before ischemia or just after reperfusion, but not 30 min after reperfusion, protects the stunned myocardium in swine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiotonic Agents; Disease Models, Animal; | 2008 |